201 related articles for article (PubMed ID: 20101022)
1. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways.
Stein R; Gupta P; Chen X; Cardillo TM; Furman RR; Chen S; Chang CH; Goldenberg DM
Blood; 2010 Jun; 115(25):5180-90. PubMed ID: 20101022
[TBL] [Abstract][Full Text] [Related]
2. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
5. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
7. Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMab.
Zhao L; Xie F; Tong X; Li H; Chen Y; Qian W; Duan S; Zheng J; Zhao Z; Li B; Zhang D; Zhao J; Dai J; Wang H; Hou S; Guo Y
MAbs; 2014; 6(3):740-8. PubMed ID: 24670986
[TBL] [Abstract][Full Text] [Related]
8. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
Carlo-Stella C; Di Nicola M; Turco MC; Cleris L; Lavazza C; Longoni P; Milanesi M; Magni M; Ammirante M; Leone A; Nagy Z; Gioffrè WR; Formelli F; Gianni AM
Cancer Res; 2006 Feb; 66(3):1799-808. PubMed ID: 16452241
[TBL] [Abstract][Full Text] [Related]
9. Positive signaling through CD72 induces mitogen-activated protein kinase activation and synergizes with B cell receptor signals to induce X-linked immunodeficiency B cell proliferation.
Wu HJ; Venkataraman C; Estus S; Dong C; Davis RJ; Flavell RA; Bondada S
J Immunol; 2001 Aug; 167(3):1263-73. PubMed ID: 11466342
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
11. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
12. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
13. Anti-class II -DR humanized monoclonal antibody, IMMU-114, blocks allogeneic immune response.
Park KH; Sawada T; Murakami T; Ishii Y; Yasuo M; Fuchinoue S; Goldenberg DM; Kubota K
Am J Surg; 2012 Oct; 204(4):527-34. PubMed ID: 22658578
[TBL] [Abstract][Full Text] [Related]
14. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
[TBL] [Abstract][Full Text] [Related]
15. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
[TBL] [Abstract][Full Text] [Related]
16. Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases.
Matsuoka T; Tabata H; Matsushita S
J Immunol; 2001 Feb; 166(4):2202-8. PubMed ID: 11160273
[TBL] [Abstract][Full Text] [Related]
17. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Dai Y; Rahmani M; Pei XY; Khanna P; Han SI; Mitchell C; Dent P; Grant S
Blood; 2005 Feb; 105(4):1706-16. PubMed ID: 15494423
[TBL] [Abstract][Full Text] [Related]
19. Extracellular signal-regulated kinase-2, but not c-Jun NH2-terminal kinase, activation correlates with surface IgM-mediated apoptosis in the WEHI 231 B cell line.
Lee JR; Koretzky GA
J Immunol; 1998 Aug; 161(4):1637-44. PubMed ID: 9712025
[TBL] [Abstract][Full Text] [Related]
20. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
